DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Status:
RECRUITING
Trial end date:
2030-06-01
Target enrollment:
Participant gender:
Summary
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.